AYTU BIOPHARMA, INC Restructuring Costs
AYTU BIOPHARMA, INC (AYTU) reported Restructuring Costs of $3.10 million for the 12-month period ending 2024-06-30, per its 10-K filed 2024-09-26.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:RestructuringCosts · last filed 2024-09-26
- AYTU BIOPHARMA, INC restructuring costs for the quarter ending 2024-06-30 was $2.85M.
- AYTU BIOPHARMA, INC restructuring costs for the quarter ending 2024-03-31 was $244.00K.
- AYTU BIOPHARMA, INC restructuring costs for the quarter ending 2023-03-31 was $0.00.
- AYTU BIOPHARMA, INC restructuring costs for fiscal 2024 was $3.10M.
| Period end | Restructuring Costs 3 month | Restructuring Costs 6 month | Restructuring Costs 9 month | Restructuring Costs 12 month |
|---|---|---|---|---|
| 2024-06-30 | $2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-26 | $3.10M derived: sum of 2 quarters · filed 2024-09-26 | $3.10M 10-K · filed 2024-09-26 | |
| 2024-03-31 | $244.00K 10-Q · filed 2024-05-15 | $244.00K 10-Q · filed 2024-05-15 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-15 | $0.00 10-Q · filed 2024-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |